Introducing PSV359 – a novel FAP-targeting peptide! It is a significant addition to our clinical pipeline as we continue to advance targeted #alphatherapeutics to fight #cancers. Learn more about our pipeline: https://lnkd.in/e3G62Def #nuclearmedicine #radiopharma #oncology
Fantastic idea
🔥Don't miss this article from ESMO - European Society for Medical Oncology on how oligoprogression in metastatic #NSCLC could be effectively treated with SBRT plus standard-of-care ✅CURB study provides the first randomised evidence of benefit from SBRT in patients with oligoprogressive NSCLC ✅Analysis of #ctDNA from CURB study provides a valuable insight into potential utility of this technology Read here👇 https://ow.ly/4K0550QpunV #MedEd #Oncology
This book provides the readers with the latest advances and insights in the ever-expanding field of Cardio-Oncology. https://bit.ly/43xTzsH #cardiooncology #cardiotoxicity #inflammation #vasculartoxicity #systemichypertension #arrhythmias #heartfailure #biomarkers #metabolomics #oncology
Dont forget to register for our June webinar! Details below
Be sure to register for our next upcoming June webinar, "Current State of FAP Ligands for Diagnostic Use in Oncology", presented by our Chief Scientific Officer Sherly Mosessian. The webinar is scheduled for June 14th at 3:30pm EST. To register: https://lnkd.in/ewnfcacB #FAPI #oncology #petct #SOFIE #education
| BioPharma Practice Leader | Market Access | BD, Licensing & Partnerships | Commercial Strategy | Research & Analysis | Strategic Intelligence |
It gives us a great pleasure to join ESMO - European Society for Medical Oncology Asia Congress in Singapore from EOS Intelligence. Exciting insights and new learnings! Day two was full of lively and engaging sessions. I found the session in drug development on ADC and RAS-RAF signalling in solid tumors very engaging. Looking forward to connect with other professionals from the 3rd and concluding day of the conference. #esmo2023 #oncology #oncologyresearch #competitiveintelligence #marketaccess #marketresearch #insights #eosintelligence #perspectives
Ultimately, the quality of biospecimen, and the resulting data, can make or break the therapeutic potential a medicine has to offer. Learn more about how Indivumed Therapeutics’ position at the forefront of sample collection and advanced analytics ensures that the most effective precision therapies get to the relevant patient subgroups when they need them in this article from Labiotech: https://bit.ly/3N5JrjX #BeyondGenomics #Oncology
Hummingbird Bioscience : Positive Phase I Clinical Data for HMBD-001 (anti-HER3 antibody) Monotherapy Trial targeting multiple solid tumors https://lnkd.in/dg5wveiX #oncology #clinicaltrials #drugdevelopment Hummingbird Bioscience
We are presenting data of sunvozertinib showing the “Best-in-Class” potential in advanced NSCLC with exon20ins mutations and encouraging anti-tumor efficacy in pretreated advanced NSCLC after failure of EGFR TKI treatment. #asco23 #Exon20ins #NSCLC #oncology
Targeted alpha therapy shows significant promise to benefit advanced stage cancer patients. Check out this webinar to learn about alpha radionuclides, their effect on tumors and how molecular imaging can be used to guide clinical translation of alpha emitting radiopharmaceutical therapies: https://hubs.ly/Q01VGz2R0 #radiopharmaceuticals #theranostics #oncology #radioligandtherapy #imagingCRO
In our latest Oncology Consortia newsletter, learn about data from a Phase 1 trial of MB-101 IL13Rα2-targeted CAR T-cells in high-grade Glioma published in Nature Medicine, and more: https://bit.ly/49PlOGl #clinicaltrialnews #oncology
Connecting Biotech to Cutting-Edge Imaging Solutions for Clinical Trials
2wSo excited to see the progress!